Related Experiment Video
Updated: Feb 21, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
AGXT2: An unnegligible aminotransferase in cardiovascular and urinary systems
Xiao-Lei Hu1, Mu-Peng Li1, Pei-Yuan Song1
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China.
Insights
Alanine-glyoxylate aminotransferase 2 (AGXT2) impacts cardiovascular diseases (CVDs) and renal impairment by regulating dimethylarginine levels. AGXT2 deficiency may contribute to disease progression, highlighting its role in cardiorenal health.
Area of Science:
- Biochemistry
- Cardiology
- Nephrology
Background:
- Cardiovascular diseases (CVDs) and renal impairment exhibit complex interactions.
- Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are implicated in CVD development and prognosis.
- ADMA and SDMA plasma levels correlate with renal function.
Purpose of the Study:
- To investigate the role of Alanine-glyoxylate aminotransferase 2 (AGXT2) in cardiovascular and renal diseases.
- To explore the impact of AGXT2 on ADMA/SDMA metabolism and its potential contribution to disease progression.
Main Methods:
- Review of existing literature on AGXT2 function and metabolism.
- Analysis of studies linking AGXT2 to cardiovascular and renal systems.
- Discussion of the relationship between AGXT2, ADMA/SDMA levels, and disease pathogenesis.
Main Results:
- AGXT2 is involved in the metabolism of ADMA and SDMA.
- AGXT2 deficiency may influence ADMA/SDMA levels, potentially affecting cardiorenal health.
- Clinical studies show associations between AGXT2 and cardiovascular/urinary system conditions.
Conclusions:
- AGXT2 plays a significant role in regulating dimethylarginine levels, impacting cardiorenal health.
- Understanding AGXT2's function offers insights into the pathogenesis of CVDs and renal diseases.
- Further research into AGXT2 may reveal novel therapeutic targets for cardiorenal conditions.
Abstract:
Cardiovascular diseases (CVDs) and renal impairment interact in a complex and interdependent manner, which makes clarification of possible pathogenesis between CVDs and renal diseases very challenging and important. There is increasing evidence showing that both asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) play a crucial role in the development of CVDs as well as in the prediction of cardiovascular events. Also, the plasma levels of ADMA and SDMA were reported to be significantly associated with renal function. Alanine-glyoxylate aminotransferase 2 (AGXT2) is reported to be involved in ADMA and SDMA metabolism, thus deficiency in the expression or activity of AGXT2 may play a part in the progression of cardiovascular or renal diseases through affecting ADMA/SDMA levels. Here, we focused our attention on AGXT2 and discussed its potential impact on CVDs and renal diseases. Meanwhile, the review also summarized the functions and recent advances of AGXT2, as well as the clinical association studies of AGXT2 in cardiovascular and urinary systems, which might arouse the interest of researchers in these fields.
More Related Videos
12:48Measuring Cation Transport by Na,K- and H,K-ATPase in Xenopus Oocytes by Atomic Absorption Spectrophotometry: An Alternative to Radioisotope Assays
Published on: February 19, 2013
07:21Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
Related Concept Videos
Aquaporins
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Active Transport
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...